Bromelain vs Serrapeptase for inflammation — which proteolytic enzyme has real evidence?
Both are "systemic enzymes" — proteolytic preparations sold for inflammation, post-surgical recovery, sinus issues, and assorted "fibrin and mucus" claims. Bromelain (from pineapple) has the larger and more credible trial base — multiple small RCTs in post-surgical edema, sinusitis, and knee OA. Serrapeptase (from silkworm gut bacteria) has a much smaller and methodologically weaker literature, mostly from a single Japanese pharmaceutical (Serratiopeptidase Takeda) that was withdrawn from the Japanese market in 2011 after failed re-examination of efficacy. The marketing for both still vastly outruns the evidence.
Quick verdict
| Complaint | Better choice | Why |
|---|---|---|
| Post-surgical edema (dental, ENT, ortho) | Bromelain | Multiple small RCTs across surgical contexts show reductions in swelling/bruising; serrapeptase has a smaller and less-replicated set. |
| Acute sinusitis (adjunct) | Bromelain | German RCT data support adjunct use; serrapeptase has older Japanese studies but unconvincing modern replication. |
| Knee OA symptomatic relief | Bromelain | Trial signals (modest), enzyme combination products studied as alternatives to NSAIDs. |
| Chronic inflammatory complaints / "anti-fibrosis" | Neither (oversold) | The "dissolves scar tissue/atherosclerosis" claims for serrapeptase are not supported by RCT data; bromelain has narrower indications. |
| Persistent post-COVID mucus / breast engorgement | Serrapeptase (modest case) | Small trials in mucolytic indications and lactational breast engorgement — limited but the cleanest serrapeptase signal. |
| DOMS / exercise recovery | Bromelain (mixed) | Trials are mixed; effect smaller than tart cherry or omega-3 for DOMS. |
How they compare on the things that matter
Mechanism — pineapple protease vs silkworm-derived protease
Bromelain is a mixture of proteolytic enzymes derived from the stem and fruit of the pineapple plant (Ananas comosus). Its proposed mechanisms include fibrinolytic activity, modulation of bradykinin-mediated edema, modulation of cell-surface adhesion molecules, and modulation of prostaglandin pathways. A small percentage of intact enzyme survives transit through the gut and reaches systemic circulation.
Serrapeptase is a serine protease originally isolated from Serratia bacteria living symbiotically in the gut of silkworms. The mechanistic claims include fibrin degradation, breakdown of "non-living" tissue, and reduction of bradykinin-related inflammatory mediators. The case for meaningful systemic absorption after oral ingestion is contested; the strongest historical claims relied on Japanese clinical work that did not survive re-examination by the Japanese regulatory agency.
Evidence base by clinical endpoint
- Post-surgical edema: Bromelain has multiple small RCTs in dental, sinus, and orthopaedic surgery showing reduced swelling and bruising at doses of 500–1000 mg/day for 5–7 days post-op. Serrapeptase has smaller trials in similar contexts with positive signals but worse methodological quality.
- Acute sinusitis: Bromelain has German adjunct data (Braun 2005); serrapeptase has older Japanese trials but no convincing modern replication.
- Knee OA: Combination enzyme products containing both have been studied as NSAID alternatives; head-to-head data on the individual enzymes are limited.
- Carpal tunnel and chronic mucolytic indications: Serrapeptase has small mucolytic and post-laryngectomy trial data; effect sizes modest.
- Breast engorgement in lactating women: Serrapeptase has older trial data showing reductions in induration and pain; one of the cleaner serrapeptase signals, though still small and old.
- "Atherosclerosis dissolution" and "scar tissue": No credible trial evidence supports these claims for either enzyme — common online marketing, but absent in the trial literature.
Dose and form
For bromelain: dose is reported in GDU (gelatin digesting units) or MCU (milk clotting units); trial doses run 500–1000 mg/day at 1500–2400 GDU/g activity. Take on an empty stomach (60+ minutes before or after meals) for systemic anti-inflammatory effect; taken with food it just digests dietary protein.
For serrapeptase: dose is reported in SU (serrapeptase units); trial doses run 10–60 mg/day (which is the dose-by-mass) at 80,000–120,000 SU/day. Enteric-coated capsules are essential — the enzyme is destroyed in stomach acid otherwise. Take on an empty stomach.
Safety
Bromelain is well-tolerated. Main cautions: theoretical additive antiplatelet effect with anticoagulants, pineapple allergy, and discontinuation 2 weeks pre-surgery to avoid additive bleeding risk. GI upset and rare allergic reactions are the most common adverse effects.
Serrapeptase is well-tolerated at trial doses. The Japanese regulatory withdrawal was for inefficacy, not safety. Case reports include pneumonitis and skin reactions; bleeding risk is theoretical, with the same antiplatelet/anticoagulant caveat as bromelain. Discontinue 2 weeks pre-surgery.
What the price difference buys you
Bromelain runs $0.20–0.50/day at trial doses. Serrapeptase runs $0.30–0.80/day at enteric-coated, properly-dosed trial-equivalent products. "Systemic enzyme blends" combining both with rutin and other components typically charge premium prices for sub-therapeutic doses of each individual enzyme.
Who should skip each
Both should be avoided in users on anticoagulants or antiplatelets without prescriber discussion, in pregnancy and lactation due to limited data (note serrapeptase is sometimes used for lactational engorgement under clinician care), pre-surgery for 2 weeks, and in known protein allergies (pineapple for bromelain).
What we'd actually buy
For post-procedural swelling and bruising in a planned surgery with surgeon sign-off: bromelain 500 mg three times daily on an empty stomach for 5–7 days post-op. Discontinue at the surgeon's pre-op cutoff.
For specific serrapeptase-supported indications (lactational engorgement under lactation-medicine support, certain mucolytic adjuncts): enteric-coated serrapeptase at 10–20 mg three times daily. For the broader anti-inflammatory marketing context, the evidence does not support the spend.
Sources
- Pavan R, et al. Properties and therapeutic application of bromelain: a review. Biotechnol Res Int. 2012;2012:976203. PMID: 23304525
- Braun JM, et al. Therapeutic use, efficiency and safety of the proteolytic pineapple enzyme Bromelain-POS in children with acute sinusitis in Germany. In Vivo. 2005;19(2):417–421. PMID: 15796205
- Brien S, et al. Bromelain as a treatment for osteoarthritis: a review of clinical studies. Evid Based Complement Alternat Med. 2004;1(3):251–257. PMID: 15841258
- Mazzone A, et al. Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind, randomized trial versus placebo. J Int Med Res. 1990;18(5):379–388. PMID: 2257960
- Bhagat S, et al. Serratiopeptidase: a systematic review of the existing evidence. Int J Surg. 2013;11(3):209–217. PMID: 23380245
- Tachibana M, et al. A multi-centre, double-blind study of serrapeptase versus placebo in post-antrotomy buccal swelling. Pharmatherapeutica. 1984;3(8):526–530. PMID: 6364134